Skip to content

Effects of skin and grape seed syrup on obese subjects

Effects of the supplementation of skin and seed extract of the São Francisco Valley grapes on cardiovascular, glycemic, lipidic, inflammatory responses and quality of life of adolescents and adults with excess weight

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
REBEC
Registry ID
RBR-29vkvt
Enrollment
Unknown
Registered
2018-10-26
Start date
2018-03-08
Completion date
Unknown
Last updated
2025-10-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Sedentary Lifestyle

Interventions

Experimental group: 20 obese subjects will be instructed to take 1.5 ml of syrup containing skin extract and grape seed once a day (equivalent to 600 mg of the extract per dose). Control group: 20 obe
Dietary supplement
SP6.051.227

Sponsors

Universidade Federal do Vale do São Francisco (UNIVASF)
Lead Sponsor
Universidade Federal do Vale do São Francisco (UNIVASF)
Collaborator

Eligibility

Age
20 Years to 59 Years

Inclusion criteria

Inclusion criteria: Body mass index above 30 kg / m2; be sedentary.

Exclusion criteria

Exclusion criteria: Have diabetes mellitus; have systemic arterial hypertension; be using any method of weight loss either through lifestyle modifications, pharmacological treatment or any antioxidant and anti-inflammatory supplementation.

Design outcomes

Primary

MeasureTime frame
Expected outcome 1: Decreased blood pressure, verified by the Microlife device (model BP 3AC1 PC), from the observation of a variation of at least 5 to 6% in the systolic and 4% to 7% in the diastolic in the pre and post intervention.;Expected outcome 2: Decreased c-reactive protein rate, verified by laboratory tests, based on a reduction of 1 mg/l in pre and post intervention measurements.;Expected outcome 3: Reduction of total cholesterol, LDL-cholesterol and triglycerides, verified by laboratory tests, based on a 14 mg/dl, 13 mg/dl and 19 mg/dl variation, respectively, in the pre and post intervention measurements.

Secondary

MeasureTime frame
Secondary outcomes are not expected.

Countries

Brazil

Contacts

Public ContactFerdinando Carvalho

Universidade Federal do Vale do São Francisco (UNIVASF)

ferdinando.carvalho@univasf.edu.br+ 55 87 2101-6856

Outcome results

None listed

Source: REBEC (via WHO ICTRP)